生物标志物风险评估模型确定了患有癌症的高风险患者,他们受益于血栓预防治疗
Sander Veldhuyzen van Zanten1, Bruce Ritchie1
1University of Alberta, Edmonton, Alberta, Canada (S.V.V., B.R.).
Annals of internal medicine
|February 5, 2024
概括
该TARGET-TP试验发现,风险导向的门诊血栓预防没有显著减少肺癌或胃肠道癌症患者的静脉血栓栓塞发生. 与标准护理相比,这种方法在重大出血事件中没有显著差异.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 静脉血栓栓塞 (VTE) 是患有肺癌和胃肠道癌症的患者常见的并发症.
- 预防策略旨在预防VTE,但需要仔细评估风险.
- 门诊性血栓预防提供了一个潜在的门诊管理策略.
研究的目的:
- 与癌症患者的标准护理相比,评估风险导向的门诊血栓预防策略的有效性和安全性.
- 为了确定这种有针对性的方法是否可以减少肺部和胃肠道恶性病的门诊患者的VTE发病率.
主要方法:
- TARGET-TP试验是一项随机临床试验,将风险导向的门诊血栓预防与标准护理进行比较.
- 患有肺癌或胃肠道癌症的患者根据VTE风险因素进行了分层.
- 结局包括VTE和重大出血事件的发生率.
主要成果:
- 主要结局,即静脉瘤综合发病率,在风险定向预防组和标准护理组之间没有显著差异.
- 在两个治疗臂之间,主要出血事件的发生率没有显著差异.
- 亚组分析没有显示出以风险为导向的方法的显著好处.
结论:
- 以风险为导向的门诊血栓预防治疗对于预防肺癌和胃肠道癌症的门诊患者的静脉动脉瘤的标准护理并不优越.
- 目前的风险分层模型可能需要改进,以优化这一群体的血栓预防治疗.
- 需要进一步的研究来确定癌症患者的最佳VTE预防策略.
更多相关视频
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.4K
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.5K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
128
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
128
01:21Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348